# US 2010/0168039 A1 · Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168039 A1
- Document ID: US20100168039A1
- Status: Published application
- Kind: A1
- Application number: 11/993,463
- Filed: 2006-06-21
- Published: 2010-07-01
- Earliest claimed: 2005-06-22
- Assignees: AstraZeneca AB
- Inventors: Susanne Alenfalk; Mikael Dahlstrom; Fana Hunegnaw; Staffan Karlsson; Ingemar Starke
- Web page: https://patentgrep.com/patent/US20100168039A1

## CPC

- C07D 405/12: linked by a chain containing hetero atoms as chain links
- A61P 3/06: Antihyperlipidemics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.

## Claims

### Claim 1

A compound of formula (I):
wherein:
X is —CH2—, —CH2CH2—, or —CH2CH2CH2—;
R1 is H, C1-6 alkyl, C3-6cycloalkyl or aryl;
R2 and R3 are, independently, hydrogen, a branched or unbranched C1-6alkyl, C3-6cycloalkyl or aryl; wherein said C1-6alkyl may be optionally substituted by one or more hydroxy, amino, guanidino, carbamoyl, carboxy, C1-6alkoxy, (C1-C4alkyl)3Si, N—(C1-6alkyl)amino, N,N-(C1-6alkyl)2-amino, C1-6alkylS(O)a wherein a is 0-2, C3-6cycloalkyl or aryl; and wherein any aryl group may be optionally substituted by one or two substituents selected from halo, hydroxy, cyano, C1-6alkyl and C1-6alkoxy;
R4 is hydrogen, C1-6 alkyl, or aryl C1-6 alkyl;
wherein R3 and R2 may form a ring with 3-7 carbon atoms and wherein R4 and R2 may form a ring with 2-6 carbon atoms; and
R5 is selected from hydrogen, halo, nitro, cyano, hydroxy, carboxy, carbamoyl, sulphamoyl, C1-6alkyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N—(C1-6alkyl)amino, N,N—(C1-6alkyl)2-amino, C1-6alkanoylamino, N—(C1-6alkyl)carbamoyl, N,N—(C1-6alkyl)2-carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N—(C1-6alkyl)sulphamoyl and N,N—(C1-6alkyl)2sulphamoyl;
or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

### Claim 2

A compound of formula (I2):
wherein:
X is —CH2—, —CH2CH2—, or —CH2CH2CH2—;
R1 is H, C1-6 alkyl, C3-6cycloalkyl or aryl;
R2 and R3 are, independently, hydrogen, a branched or unbranched C1-6alkyl, C3-6cycloalkyl or aryl; wherein said C1-6alkyl may be optionally substituted by one or more hydroxy, amino, guanidino, carbamoyl, carboxy, C1-6alkoxy, (C1-C4alkyl)3Si, N—(C1-6alkyl)amino, N,N—(C1-6alkyl)2-amino, C1-6alkylS(O)a wherein a is 0-2, C3-6cycloalkyl or aryl; and wherein any aryl group may be optionally substituted by one or two substituents selected from halo, hydroxy, cyano, C1-6alkyl OF and C1-6alkoxy;
R4 is hydrogen, C1-6 alkyl, or arylC1-6 alkyl;
wherein R3 and R2 may form a ring with 3-7 carbon atoms and wherein R4 and R2 may form a ring with 2-6 carbon atoms; and
R5 is selected from hydrogen, halo, nitro, cyano, hydroxy, carboxy, carbamoyl, sulphamoyl, C1-6 alkyl, C1-6alkoxy, C1-6 alkanoyl, C1-6 alkanoyloxy, N—(C1-6 alkyl)amino, N,N—(C1-6 alkyl)2-amino, C1-6alkanoylamino, N—(C1-6 alkyl)carbamoyl, N,N—(C1-6alkyl)2-carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N—(C1-6alkyl)sulphamoyl and N,N—(C1-6 alkyl)2sulphamoyl;
or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

### Claim 3 (depends on 1)

A compound according to claim 1, wherein X is —CH2—.

### Claim 4 (depends on 1)

A compound according to claim 1, wherein X is —CH2CH2—.

### Claim 5 (depends on 1)

A compound according to claim 1, wherein X is —CH2CH2CH2—.

### Claim 6 (depends on 1)

A compound according to claim 1, wherein,
R1 is hydrogen;
R2 and R3 are, independently, hydrogen or a branched or unbranched C1-6alkyl; wherein said C1-6alkyl is substituted by C3-6cycloalkyl, aryl or amino; and
R4 is hydrogen.

### Claim 7 (depends on 1)

A compound according to claim 1 wherein,
R1 is hydrogen;
R2 and R3 are, independently, hydrogen or a branched or unbranched C1-6alkyl; wherein said C1-6alkyl is substituted by C3-6cycloalkyl; and
R4 is hydrogen.

### Claim 8 (depends on 7)

A compound according to claim 7, wherein, R2 is hydrogen and R3 is tert-butyl.

### Claim 9 (depends on 7)

A compound according to claim 7, wherein, R2 is hydrogen and R3 is methyl; wherein said methyl is substituted by cyclolohexyl.

### Claim 10 (depends on 1)

A compound according to claim 1, wherein, R5 is selected from chlorine or fluorine.

### Claim 11

One or more compounds selected from:
N-({4-[(2R,3R)-3-{[2-(1,3-Benzodioxol-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-cyclohexyl-D-alanine;
N-({4-[(2R,3R)-3-{[2-(1,3-Benzodioxol-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-methyl-D-valine;
N-({4-[(2R,3R)-3-{[(2R)-2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-methyl-D-valine; and
N-({4-[(2R,3R)-3-{[(2R)-2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]thio}-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-cyclohexyl-D-alanine.

### Claim 12

A compound of the formula (XVI):
wherein:
X is —CH2—, —CH2CH2—, or —CH2CH2CH2—;
R1 is hydrogen, C1-6 alkyl, C3-6cycloalkyl or aryl;
R5 is selected from halo, nitro, cyano, hydroxy, carboxy, carbamoyl, sulphamoyl, C1-6alkyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N—(C1-6alkyl)amino, N,N—(C1-6alkyl)2-amino, C1-6alkanoylamino, N—(C1-6alkyl)carbamoyl, N,N—(C1-6alkyl)2-carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N—(C1-6alkyl)sulphamoyl and N,N—(C1-6alkyl)2sulphamoyl; and
R7 is an hydroxy group or a C1-4 alkoxy group.

### Claim 13 (depends on 1)

A method of treating or preventing hyperlipidemic conditions comprising the administration of an effective amount of a compound according to claim 1 to a mammal in need thereof.

### Claim 14 (depends on 1)

A method of treating or preventing atherosclerosis comprising the administration of an effective amount of a compound according to claim 1 to a mammal in need thereof.

### Claim 15 (depends on 1)

A method for treating or preventing Alzheimers' disease comprising the administration of an effective amount of a compound according to claim 1 to a mammal in need thereof.

### Claim 16 (depends on 1)

A method for treating or preventing cholesterol associated tumors comprising the administration of an effective amount of a compound according to claim 1 to a mammal in need thereof.

### Claim 17 (depends on 1)

A pharmaceutical formulation comprising a compound according to claim 1 in admixture with a pharmaceutically acceptable adjuvant, diluent and/or carrier.

### Claim 18

A process for preparing a compound of formula (I)
wherein:
X is —CH2— —CH2CH2— or —CH2CH2CH2—;
R1 is H, C1-6 alkyl, C3-6cycloalkyl or aryl;
R2 and R3 are, independently, hydrogen, a branched or unbranched C1-6alkyl, C3-6cycloalkyl or aryl; wherein said C1-6alkyl may be optionally substituted by one or more hydroxy, amino, guanidino, carbamoyl, carboxy, C1-6alkoxy, (C1-C4alkyl)3Si N—(C1-6alkyl)amino, N,N—(C1-6alkyl)2-amino, C1-6alkylS(O)a wherein a is 0-2, C3-6cycloalkyl or aryl; and wherein any aryl group may be optionally substituted by one or two substituents selected from halo, hydroxy, cyano, C1-6alkyl, and C1-6alkoxy;
R4 is hydrogen, C1-6 alkyl, or arylC1-6 alkyl;
wherein R3 and R2 may form a ring with 3-7 carbon atoms and wherein R4 and R2 may form a ring with 2-6 carbon atoms; and
R5 is selected from hydrogen, halo, nitro, cyano, hydroxy, carboxy, carbamoyl, sulphamoyl, C1-6 alkyl, C1-6alkoxyl, C1-6alkanoyl, C1-6alkanoyloxy, N—(C1-6alkyl)amino, N,N—(C1-6 alkyl)2-amino, C1-6alkanoylamino, N—(C1-6 alkyl)carbamoyl, N,N—(C1-6alkyl)2-carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N—(C1-6alkyl)sulphamoyl and N,N—(C1-6 alkyl)2sulphamoyl;
or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof which process (wherein variable groups are, unless otherwise specified, as defined in formula (I)) comprises any of the steps:
Process 1) reacting a compound of formula (II2):
with a compound of formula (III):
wherein L is a displaceable group; or
Process 2) reacting an acid of formula (IV2):
or an activated derivative thereof; with an amine of formula (V):
or
Process 3): reacting an acid of formula (VI2):
or an activated derivative thereof, with an amine of formula (VII):
or
Process 4): reducing a compound of formula (VIII2):
or
Process 5): reacting a compound of formula (IX2):
with a compound of formula (X):
wherein L is a displaceable group; or
Process 6): reacting a compound of formula (XI2):
wherein L is a displaceable group; with a compound of formula (XII):
or
Process 7): De-esterifying a compound of formula (XIII2)
wherein the group C(O)OR is an ester group.

### Claim 19 (depends on 2)

A compound according to claim 2, wherein X is —CH2—.

### Claim 20 (depends on 2)

A compound according to claim 2, wherein X is —CH2CH2—.

### Claim 21 (depends on 2)

A compound according to claim 2, wherein X is —CH2CH2CH2—.

### Claim 22 (depends on 2)

A compound according to claim 2, wherein, R1 is hydrogen;
R2 and R3 are, independently, hydrogen or a branched or unbranched C1-6alkyl; wherein said C1-6alkyl is substituted by C3-6cycloalkyl, aryl or amino; and
R4 is hydrogen.

### Claim 23 (depends on 2)

A compound according to claim 2 wherein,
R1 is hydrogen;
R2 and R3 are, independently, hydrogen or a branched or unbranched C1-6alkyl; wherein said C1-6alkyl is substituted by C3-6cycloalkyl; and
R4 is hydrogen.

### Claim 24 (depends on 23)

A compound according to claim 23, wherein, R2 is hydrogen and R3 is tert-butyl.

### Claim 25 (depends on 23)

A compound according to claim 23, wherein, R2 is hydrogen and R3 is methyl; wherein said methyl is substituted by cyclolohexyl.

### Claim 26 (depends on 2)

A compound according to claim 2, wherein, R5 is chlorine or fluorine.

### Claim 27 (depends on 2)

A method of treating or preventing hyperlipidemic conditions comprising the administration of an effective amount of a compound according to claim 2 to a mammal in need thereof.

### Claim 28 (depends on 2)

A method of treating or preventing atherosclerosis comprising the administration of an effective amount of a compound according to claim 2 to a mammal in need thereof.

### Claim 29 (depends on 2)

A method for treating or preventing Alzheimers' disease comprising the administration of an effective amount of a compound according to claim 2 to a mammal in need thereof.

### Claim 30 (depends on 2)

A method for treating or preventing cholesterol associated tumors comprising the administration of an effective amount of a compound according to claim 2 to a mammal in need thereof.

### Claim 31 (depends on 2)

A pharmaceutical formulation comprising a compound according to claim 2 in admixture with a pharmaceutically acceptable adjuvant, diluent and/or carrier.

### Claim 32 (depends on 12)

A method of treating or preventing hyperlipidemic conditions comprising the administration of an effective amount of a compound according to claim 12 to a mammal in need thereof.

### Claim 33 (depends on 12)

A method of treating or preventing atherosclerosis comprising the administration of an effective amount of a compound according to claim 12 to a mammal in need thereof

### Claim 34 (depends on 12)

A method for treating or preventing Alzheimers' disease comprising the administration of an effective amount of a compound according to claim 12 to a mammal in need thereof.

### Claim 35 (depends on 12)

A method for treating or preventing cholesterol associated tumors comprising the administration of an effective amount of a compound according to claim 12 to a mammal in need thereof.

### Claim 36 (depends on 12)

A pharmaceutical formulation comprising a compound according to claim 12 in admixture with a pharmaceutically acceptable adjuvant, diluent and/or carrier.

### Claim 37 (depends on 12)

A pharmaceutical formulation comprising a compound according to claim 12 in admixture with a pharmaceutically acceptable adjuvant, diluent and/or carrier.
